Pharm'Up 
Anixa Biosciences, a clinical-stage biotech company specializing in cancer treatment, has announced the issuance of a new U.S. patent (No. 12,384,826) for its innovative CAR-T technology. This patent is a significant milestone, as it extends the company’s protection for its core CAR-T platform until 2045. The technology, which was originally developed by The Wistar Institute and is exclusively licensed to Anixa, is designed to overcome the limitations of traditional CAR-T therapies when used against solid tumors.
A Unique Approach to Cancer Treatment
Anixa’s CAR-T platform is currently being evaluated in a clinical trial at the Moffitt Cancer Center for the treatment of recurrent ovarian cancer. The company’s pipeline also includes a distinct therapeutic approach called chimeric endocrine receptor-T cell (CER-T) technology, which targets ovarian cancer by using a natural ligand (FSH) to bind to tumor cells, a novel method compared to the antibody fragments used in standard CAR-T treatments.
Beyond its CAR-T and CER-T programs, Anixa is also collaborating with the Cleveland Clinic to develop a portfolio of cancer vaccines. These vaccines aim to prevent and treat various cancers, including breast, ovarian, lung, colon, and prostate cancers, by targeting “retired” proteins found in these malignancies.
According to Dr. Amit Kumar, the CEO of Anixa Biosciences, this new patent protection is a crucial step for the clinical and commercial success of their CAR-T program. The company’s strategic partnerships with leading research institutions such as The Wistar Institute, Moffitt Cancer Center, and Cleveland Clinic underscore its commitment to developing breakthrough immunotherapies and solidifying its position as a key innovator in the field of oncology.
About the Author
